麻豆传媒

The FDA cleared the transcranial magnetic stimulation system for the treatment of obsessive-compulsive disorder, Neuronetics announced. The system was previously cleared for major depressive disorder.

Depression and anxiety were linked with a higher rate of accumulating in young men and women. (JAMA Network Open)

The online said it will no longer write scripts for attention-deficit/hyperactivity disorder medications, including Adderall and Ritalin, now that the Drug Enforcement Agency launched an investigation into reports of overprescribing. (Fierce Healthcare)

Are the FDA's blocking patients with treatment-resistant schizophrenia from access to treatment? (STAT)

Females ages 8 to 19 who attempted suicide had a 6-fold higher risk for subsequent hospitalization for , a study from Canada found, plus a 67-fold higher risk for developing sedative or hypnotic use disorders in the 5 years after an attempt. (JAMA Psychiatry)

After failing to meet the primary endpoint, Idorsia Pharmaceuticals said it's throwing in the towel on the investigational ACT-539313, a selective orexin 1 receptor antagonist. (BioSpace)

Alzamend Neuro announced it started a phase IIa trial of its -- a novel lithium-delivery system -- for Alzheimer's-related dementia, with topline data expected in December.

Researchers at Indiana University are developing a that would automatically administer naloxone if signs of an impending overdose are detected.

Comment